Biotechnology companies that have previously exclusively sold drugs and vaccines to the federal government are diversifying their businesses to include commercial products, according to a Washington Post article. Steven Overly writes the value of such firms lag compared to commercial counterparts and the defense biotechnology firms are looking to change this. In an example of...
September 28, 2023
Hello, Guest!